Clinical trials: Leukoderma
Nonsegmental Vitiligo With Genital Involvement
A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo
An open-label study in which participants with non-segmental vitiligo with genital involvement will apply ruxolitinib 1.5% cream twice a day (BID) to all depigmented areas (up to 10% BSA) for up to 48 weeks.
- Trial name
- NCT05750823
- Testing
- Ruxolitinib Cream
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 49 people
- Sponsor
- Incyte Corporation
Vitiligo, Non-Segmental Vitiligo (NSV)
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo.
- Trial name
- NCT07533019
- Testing
- LY4005130
- Where
- 35 sites in United States, Belgium and 3 more
- Volunteers
- 66 people
- Sponsor
- Eli Lilly and Company